









市場
/
株式
/
nasdaq-mygn
/

Myriad Genetics Inc

MYGN

6.550USD

-0.010-0.15%

終値 12/24, 13:00（ET）15分遅れの株価

609.80M時価総額

損失額直近12ヶ月PER



Myriad Genetics Inc

6.550

-0.010-0.15%

概要企業名金融分析

概要

企業名

金融

分析

詳細情報 Myriad Genetics Inc 企業名

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

Myriad Genetics Incの企業情報



企業コードMYGN

会社名Myriad Genetics Inc

上場日Oct 06, 1995

最高経営責任者「CEO」Raha (Samraat S)

従業員数2700

証券種類Ordinary Share

決算期末Oct 06

本社所在地322 North 2200 West

都市SALT LAKE CITY

証券取引所NASDAQ OMX - NASDAQ BASIC

国United States of America

郵便番号84116

電話番号18015843600

ウェブサイトhttps://myriad.com/

企業コードMYGN

上場日Oct 06, 1995

最高経営責任者「CEO」Raha (Samraat S)

Myriad Genetics Incの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Brian Donnelly

Chief Commercial Officer

397.53K

Mr. Mark S. Verratti

Chief Operating Officer and Chief Commercial Officer

220.57K

-0.49%

Dr. Lee Nisley Newcomer, M.D.

Independent Director

132.14K

+60.47%

Ms. Margaret (Maggie) Ancona

Senior Vice President, Chief of Staff

127.73K

-0.74%

Ms. Rashmi Kumar

Independent Director

127.19K

+64.34%

Ms. Shereen Solaiman

Chief People Officer

110.96K

+98.89%

Mr. Benjamin Richard (Ben) Wheeler

Chief Financial Officer

92.65K

-2.69%

Dr. Dale Muzzey

Chief Scientific Officer

45.88K

-46.96%

Ms. S. Louise Phanstiel, CPA

Independent Chairman of the Board

Mr. Matt Scalo

Investor Relations

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Brian Donnelly

Chief Commercial Officer

397.53K

Mr. Mark S. Verratti

Chief Operating Officer and Chief Commercial Officer

220.57K

-0.49%

Dr. Lee Nisley Newcomer, M.D.

Independent Director

132.14K

+60.47%

Ms. Margaret (Maggie) Ancona

Senior Vice President, Chief of Staff

127.73K

-0.74%

Ms. Rashmi Kumar

Independent Director

127.19K

+64.34%

Ms. Shereen Solaiman

Chief People Officer

110.96K

+98.89%

収益内訳

通貨: USD更新時刻: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

事業別USD

会社名

収益

比率

Hereditary Cancer

96.30M

45.19%

Prenatal

47.60M

22.34%

Pharmacogenomics

37.80M

17.74%

Tumor Profiling

31.40M

14.73%

地域別USD

会社名

収益

比率

United States

198.20M

93.01%

Rest of world

14.90M

6.99%

事業別

地域別

事業別USD

会社名

収益

比率

Hereditary Cancer

96.30M

45.19%

Prenatal

47.60M

22.34%

Pharmacogenomics

37.80M

17.74%

Tumor Profiling

31.40M

14.73%

株主

更新時刻: Tue, Nov 18

株主統計

種類

株主統計

比率

BlackRock Institutional Trust Company, N.A.

14.22%

The Vanguard Group, Inc.

8.34%

State Street Investment Management (US)

5.34%

Millennium Management LLC

5.09%

Glenview Capital Management, LLC

4.92%

他の

62.09%

株主統計

比率

BlackRock Institutional Trust Company, N.A.

14.22%

The Vanguard Group, Inc.

8.34%

State Street Investment Management (US)

5.34%

Millennium Management LLC

5.09%

Glenview Capital Management, LLC

4.92%

他の

62.09%

種類

株主統計

比率

Investment Advisor

37.68%

Investment Advisor/Hedge Fund

27.22%

Hedge Fund

25.48%

Research Firm

5.93%

Individual Investor

3.28%

Pension Fund

1.73%

Bank and Trust

0.41%

Family Office

0.24%

Sovereign Wealth Fund

0.04%

機関投資家保有株



更新時刻: Wed, Oct 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q3

518

92.00M

98.69%

-11.12M

2025Q2

518

100.80M

108.34%

-1.85M

2025Q1

527

99.14M

107.57%

-4.54M

2024Q4

516

96.89M

106.12%

-1.41M

2024Q3

505

95.02M

104.61%

-5.50M

2024Q2

486

96.79M

106.52%

-6.22M

2024Q1

460

98.19M

108.68%

+613.48K

2023Q4

464

93.46M

105.77%

+2.70M

2023Q3

471

86.01M

104.78%

-3.73M

2023Q2

480

84.60M

103.32%

-6.34M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

BlackRock Institutional Trust Company, N.A.

13.43M

14.43%

-416.99K

-3.01%

Jun 30, 2025

The Vanguard Group, Inc.

9.15M

9.83%

-1.47M

-13.83%

Jun 30, 2025

State Street Investment Management (US)

4.81M

5.17%

-458.84K

-8.71%

Jun 30, 2025

Millennium Management LLC

4.92M

5.29%

+855.19K

+21.01%

Jun 30, 2025

Glenview Capital Management, LLC

4.59M

4.93%

+687.86K

+17.64%

Jun 30, 2025

D. E. Shaw & Co., L.P.

4.51M

4.85%

+1.99M

+78.84%

Jun 30, 2025

Morgan Stanley & Co. LLC

3.37M

3.63%

+1.97M

+140.14%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.22M

2.39%

-7.80K

-0.35%

Jun 30, 2025

Camber Capital Management LP

2.00M

2.15%

-350.00K

-14.89%

Jun 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

種類

比率

データなし

日付

種類

比率

データなし

よくある質問

Myriad Genetics Incの上位5名の株主は誰ですか？



Myriad Genetics Incの上位5名の株主は以下のとおりです。
BlackRock Institutional Trust Company, N.A.は13.43M株を保有しており、これは全体の14.43%に相当します。
The Vanguard Group, Inc.は9.15M株を保有しており、これは全体の9.83%に相当します。
State Street Investment Management (US)は4.81M株を保有しており、これは全体の5.17%に相当します。
Millennium Management LLCは4.92M株を保有しており、これは全体の5.29%に相当します。
Glenview Capital Management, LLCは4.59M株を保有しており、これは全体の4.93%に相当します。